Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells

Irish Journal of Medical Science

Volumn 180, Issue 4, 2011, Pages 865-872

  Wang, Y ^a   Li, J Q ^a   Shao, C ^b   Shi, C H ^c   Liu, F ^a   Yang, Z Y ^a   Qiu, J X ^a   Li, Y M ^a   Fu, Q ^a   Zhang, W ^a   Xue, W ^a   Lei, Y H ^a   Gao, J Y ^a   Wang, J Y ^a   Gao, X P ^a   Yuan, J L ^b   Bao, T Y ^a   Zhang, Y T ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Androgen receptor co regulator; Androgen dependent transition; Flutamide; Hydroxyflutamide insensitivity; Prostate cancer cell

Indexed keywords

ANDROGEN RECEPTOR; HYDROXYFLUTAMIDE; NUCLEAR RECEPTOR COACTIVATOR 2; PROSTATE SPECIFIC ANTIGEN; PROTEIN ARA70; PROTEIN NOCR1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; ELECTRON MICROSCOPY; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; UPREGULATION;

ANDROGEN ANTAGONISTS; DRUG RESISTANCE, NEOPLASM; FLUTAMIDE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; NUCLEAR RECEPTOR CO-REPRESSOR 1; NUCLEAR RECEPTOR COACTIVATOR 2; NUCLEAR RECEPTOR COACTIVATORS; PROSTATIC NEOPLASMS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 82955232905     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-011-0714-4     Document Type: Article

References (15)

1. F Herranz Amo F Arias Funez M Arrizabalaga Moreno, et al. 2003 The prostate cancer in the community of Madrid in 2000 I.- Incidence Actas Urol Esp 27 323 334 12891909 1:STN:280:DC%2BD3szlvFOhsw%3D%3D (Pubitemid 36827973)
2. FJ Drummond AE Carsin L Sharp, et al. 2010 Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines Ir J Med Sci 179 43 49 19562407 10.1007/s11845-009-0376-7 1:STN:280: DC%2BC3c%2FpvFGmsw%3D%3D
3. MF Leitzmann EA Platz MJ Stampfer, et al. 2004 Ejaculation frequency and subsequent risk of prostate cancer JAMA 291 1578 1586 15069045 10.1001/jama.291.13.1578 1:CAS:528:DC%2BD2cXjtVamsbo%3D (Pubitemid 38552430)
4. F Neumann 1982 Pharmacology and clinical use of antiandrogens: a short review Ir J Med Sci 151 61 70 7042638 10.1007/BF02940148 1:STN:280: DyaL387ovFaquw%3D%3D (Pubitemid 12103288)
5. Huggins C, Hodges CV. Studies on prostatic cancer: I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 293-297
6. P Koivisto T Visakorpi OP Kallioniemi 1996 Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer Scand J Clin Lab Investig Suppl 226 57 63 1:STN:280:DyaK2s7js1Wgsw%3D%3D
7. Y Miyoshi H Uemura K Fujinami, et al. 2000 Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients Prostate 43 225 232 10797498 10.1002/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0. CO;2-7 1:CAS:528:DC%2BD3cXjs1Wrsrs%3D (Pubitemid 30230459)
8. CW Gregory B He RT Johnson, et al. 2001 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy Cancer Res 61 4315 4319 11389051 1:CAS:528:DC%2BD3MXktlSquro%3D (Pubitemid 32685750)
9. Y Wang C Shao CH Shi, et al. 2005 Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism Asian J Androl 7 375 380 16281084 10.1111/j.1745-7262.2005.00031.x 1:CAS:528: DC%2BD28XktVyitw%3D%3D (Pubitemid 41819351)
10. C Shao Y Wang HH Yue, et al. 2007 Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase J Androl 28 804 812 17581945 10.2164/jandrol.106.002154 1:CAS:528:DC%2BD2sXhtlCqtr7L (Pubitemid 350058129)
11. R Iliescu LA Campos WP Schlegel, et al. 2003 Androgen receptor independent cardiovascular action of the antiandrogen flutamide J Mol Med 7 420 427 10.1007/s00109-003-0449-4 (Pubitemid 36900537)
12. H Klocker Z Culig F Kaspar, et al. 1994 Androgen signal transduction and prostatic carcinoma World J Urol 2 99 103
13. N Olea K Sakabe AM Soto, et al. 1990 The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP Endocrinology 126 1457 1463 2307113 10.1210/endo-126-3-1457 1:CAS:528:DyaK3cXhsFajtLs%3D (Pubitemid 20095749)
14. C Sonnenschein N Olea ME Pasanen, et al. 1989 Negative controls of cell proliferation: human prostate cancer cells and androgens Cancer Res 49 3474 3481 2731169 1:CAS:528:DyaL1MXltV2iurc%3D (Pubitemid 19178161)
15. RM Attar CH Takimoto MM Gottardis 2009 Castration-resistant prostate cancer: locking up the molecular escape routes Clin Cancer Res 15 3251 3255 19447877 10.1158/1078-0432.CCR-08-1171 1:CAS:528:DC%2BD1MXmtVKmtbY%3D